Introduction
The risk continuum of tobacco and nicotine products developed by McNeill and Munafò (McNeill and Munafò, 2013) hypothesises that exposure to toxicants and health risks differ between types of tobacco and nicotine products. Cigarettes and cigars are most harmful, and ecigarettes and medicinal nicotine products the least. Some product categories, such as snus, have extensive epidemiological data on relative health risks, whereas others, such as e-cigarettes are emerging technologies with relatively few data. Additionally, some technologies, such as those that heat rather than burn tobacco, are only very recently coming into widespread consumer use in certain markets, despite being developed and test marketed over three decades ago. In British American Tobacco (BAT) we recently presented a version of the product continuum, ordered by levels of toxicants ( Fig. 1) (British American Tobacco, 2017) . On account of emerging science on e-cigarettes (Margham et al., 2016) and Tobacco Heating Products (Schaller et al., 2016) , along with previously published data on smokeless tobacco, Snus (McAdam et al., 2013 , we proposed that the product continuum should place non-combustible tobacco and nicotine products at the low end of toxicant exposure, with cigarettes at the opposite extreme end of high toxicant exposure.
Cigarette smoking causes a range of serious diseases (Doll and Hill, 1950) in a dose-dependent manner and according to total duration of smoking (Doll, 2004) . Health risks diminish after cessation to a degree dependent on the number of smoking-years. Therefore, after complete cessation, risks can reduce and even return to never-smoker levels or disease progression may be slowed (US Department of Health and Human Services, 2014 and Stratton et al., 2001) . Accordingly, the US Institute of Medicine concluded that some of the harm caused by tobacco use might be reduced by the introduction of what it termed potential reduced-exposure products (i.e., shown through scientific studies to result in substantial reduction in exposure to one or more tobacco toxicants, leading to reduced risk of disease and adverse effects) (Stratton et al., 2001) . Which toxicants should be reduced or the degree of reduction were not specified in the Institute of Medicine report. Rather, clinical and other studies were expected to be used to determine whether toxicant reductions could reasonably be expected to result in reduced health risks.
The Institute of Medicine also noted the importance of regulatory oversight for the assessment and marketing of potential reduced-exposure products. In 2009, the US Food and Drug Administration (FDA) began regulating tobacco after the introduction of the Family Smoking Prevention and Tobacco Control Act. This legislation included the potential for the FDA to accept claims that products were potential reduced-exposure products, termed in the regulation "modified risk tobacco products" (MRTPs), through demonstration of reduced toxicant exposure and/or reduction in health risks and no adverse public health effect on the population as a whole. Subsequently, the FDA issued draft guidance on the types of studies needed (FDA, 2011) , based on recommendations by the Institute of Medicine (2011) .
The FDA formed the Tobacco Products Scientific Advisory Committee (TPSAC) and amongst other issues asked it to identify harmful or potentially harmful constituents (HPHCs) present in tobacco and tobacco smoke. Lists of key toxicants in smoke have changed over time as toxicological understanding and analytical chemical techniques have improved. For instance, a list of 300 compounds in smoke was collated by the UK Royal College of Physicians (1962) , of which around 16 were thought to be carcinogenic. Hoffmann later defined a broader list of 44 potential toxicants, which has been used by some regulators including Health Canada (Hoffmann and Hecht, 1990; Health Canada (2004) ). In 2008, a WHO study group prioritised 9 smoke toxicants in an assessment of possible regulatory approaches for reducing the harms associated with cigarette smoking (Burns et al., 2008) . The FDA eventually identified a list of around 100 toxicants that were deemed individually to have toxic or potentially toxic properties (FDA, 2011) .
Since the 1960s, many countries required manufacturers to print the mainstream smoke yields on a per cigarette basis (Nicotine Free Dry Particulate Matter, NFDPM 'tar'; Nicotine and Carbon Monoxide, CO) on the cigarette packaging, as measured under the ISO machine smoking regimen (ISO, 2001 ). In the EU, a ceiling was applied to cigarettes permitting a maximum ISO yield of NFDPM = 10mg/cig; Nicotine = 1.0mg/cig and CO = 10mg/cig (EU, 2014) . Health Canada and ANVISA (Brazil's Health Surveillance Agency) were the first regulators that required measurement and reporting of tobacco and smoke toxicants. In Canada, values for a subset of these were printed on packs of cigarettes until research showed that smokers did not understand the information. Only a small number of other regulators, including those in Venezuela, Nepal and Taiwan, have subsequently required reporting of tobacco and smoke toxicants . The FDA now mandates measurement and disclosure of values for 18 harmful and potentially harmful constituents, and is considering how to provide this information so that it will be clearly understood by smokers.
Outside the USA, many countries have ratified the World Health Organization (WHO) Framework Convention on Tobacco Control (FCTC). The WHO also encourages measurement and disclosure of values for tobacco and smoke constituents and emissions. A network of independent international analytical laboratories is working to establish standardised methods for assessment of various toxicants. A WHO scientific advisory panel, the Study Group on Tobacco Product Regulation (TobReg), has issued various reports, including a recommendation that 18 toxicants in tobacco smoke be monitored (Burns et al., 2008) , and the levels of nine be mandated for lowering (shown in Fig. 2 At BAT, we developed several toxicant reducing technologies and combined them using an optimal cigarette and blend design to produce a prototype RTP cigarette (Fig. 3) , aimed at reducing exposure to as many toxicants as feasibly possible while maintaining product acceptability from a sensorial, ritualistic and pharmacological perspective. The RTP was evaluated in a series of pre-clinical and clinical studies. This publication summarises these studies describing the totality of the data package, including pre-clinical chemical studies (Dittrich et al., 2014) , and in vitro assessments focussing on both classical toxicological (Crooks et al., 2015) and disease relevant (Oke et al., 2017) end points. Furthermore, clinical studies were conducted to assess the potential of the RTP cigarette to reduce both exposure to toxicants and subsequent individual risk relative to commercial cigarettes (Shepperd et al., 2015) . In this paper we also contextualise the findings of the RTP studies against regulatory proposals for reducing toxicant emissions from cigarettes (Burns et al., 2008) , and against recent studies of toxicant emissions from Next Generation Products (NGP) (Margham et al., 2016; Poynton et al., 2017) . Finally, we discuss here whether the scientific data collected on the RTP cigarette are consistent with reduced toxicant emission cigarettes forming a distinct category in the risk continuum.
Results

Chemistry of tobacco-smoke toxicants
Tobacco smoke is a complex mixture of gases and volatile, semivolatile, and involatile compounds that have been extensively characterised. Two tobacco-specific nitrosamines (TSNAs), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N-nitrosonornicotine (NNN), are common to most lists of toxicants (US Department of Health and Human Services, 2014). There are two principle sources of toxicants in smoke -transfer directly from the tobacco to the smoke, such as heavy metals (e.g., cadmium), and formation during combustion by pyrosynthesis or thermal breakdown e.g., carbon dioxide (CO) (Baker and Proctor, 1990) . Some toxicants, such as TSNAs, are present in smoke due to the operation of both mechanisms.
Toxicant precursor levels in tobacco blends can vary substantially dependent on the varieties of tobacco, environmental and agrochemical conditions during growing, and conditions during curing and storage (Baker, 1999) . The combustion conditions within a cigarette can also vary dependent upon several factors, including its construction, how it is smoked, and might affect individual compound yields and relative yields in smoke. Different filter materials (e.g., cellulose acetate fibres, triacetin, and active carbon) affect smoke yields differently Branton et al., 2011a,b) .
Commercial cigarettes have a wide range of toxicant yields . We have developed databases (McAdam et al., 2012; Camacho et al., 2015) of those obtained under Health Canada Intense (HCI) smoking conditions from three sources (Australian Government, Department of Health and Ageing, 2002; Counts et al., 2005 and Health Canada, 2004) , although comparisons must be treated with caution owing to limited standardisation between laboratories (Counts et al., 2005; Gregg et al., 2004 and Intorp et al., 2009 ). We removed data that were not available from all three sources (arsenic, methyl ethyl ketone, nickel, and selenium yields) or were incomplete, duplicated, or erroneous (e.g., in the Health Canada dataset two brands seemed to have erroneously exchanged toluene and styrene yields; tar, nicotine and CO yields were not provided for one brand; and multiple instances of the same yield data were observed). Finally, we removed data on reference products. The collated dataset had information on 39 toxicants in 120 cigarette brands from 16 countries or regions. Analysis showed that most toxicants, particularly nitrogenous toxicants, such as TSNAs and aromatic amines, were not normally distributed. Thus, although unlikely to be fully representative of all cigarette products on sale globally, with respect to either design features or brands, this database does constitute a reasonable comparator set for toxicant yields from reduced toxicant prototype cigarettes.
Reducing tobacco smoke toxicant yields: RTP design
Tobacco harm reduction is based on the premise that substituting conventional cigarettes with a lower risk product will produce lower levels of harm amongst smokers. Therefore, it is key that any potentially reduced risk tobacco product would have reduced toxicity in comparison to a conventional cigarette, while at the same time maintaining a level of acceptability in terms of sensory, ritual and nicotine pharmacology. The design strategy for the RTP cigarette was to consider every design feature to produce a product that could meet both of these goals.
Dittrich et al. (Dittrich et al., 2014) described the systematic study that considered the effects of cigarette circumference and filter length and concluded that a demi-slim cigarette design (c = 21.0 mm), tobacco rod and filter length of 56 mm and 37 mm respectively, produced the lowest levels of toxicant emissions. The demi-slim cigarette format was important as it enabled a total tobacco weight that was reduced versus a kingsize cigarette, but was still sufficient to deliver an acceptable sensory performance. The filter length was key as it enabled a high filter additive loading with acceptable smoking mechanics (eg. draw effort).
Several Toxicant Reducing Technologies (TRTs) were included in the RTP cigarette, to further reduce key toxicants. The key technologies were as follows:
(a) Tobacco Substitute Sheet (TSS), made from calcium carbonate, bound with sodium alginate, loaded with glycerol (approximately 12.5%), and coloured with caramel, is added to a standard tobacco blend. Upon combustion glycerol is released into smoke and replaces some of the tobacco combustion products, diluting the yields in the total NFDPM . (b) Blend Treated Tobacco (BTT), where tobacco is subjected to a treatment process involving aqueous extraction and filtration to remove a proportion of polyphenols and proteins, with insoluble tobacco proteins removed by treatment with proteases, and subsequent recombination of tobacco solids and aqueous extracts. This blend treatment reduces yields of phenolics, aromatic amines, hydrogen cyanide, and other nitrogenous smoke constituents, although increases in yields of formaldehyde and isoprene are observed . (c) Synthetic high-activity carbon (Blucher GmbH, Mettmanner, Germany) replaces the carbon typically used in charcoal filters. Spherical beads, combined with an optimised meso-/micro-pore structure improves adsorption characteristics for various volatile smoke toxicants (Branton et al., 2011a) .
Chemical Corporation, Tokyo, Japan), is incorporated into filters, which selectively reduced yields of HCN, volatile acids, and carbonyls (Branton et al., 2011b) . (e) Triethyl citrate is an alternative filter-plasticiser to triacetin, which is used in many commercial cigarette brands, and enhances the ability of the filter to reduce yields of phenols in mainstream smoke (McAdam et al., 2012) without substantially altering the physical quality of the filter. (f) Split tipping is a novel filter ventilation technology that can be used either as an alternative or in addition to conventional ventilation methods to allow diffusion of vapours and gases in and out of the filter when the cigarette is being smoked. With this design, conventional tipping paper covers the join of the filter to the tobacco rod and the mouth end of the filter, but between is an area of naturally porous paper that allows diffusion and removal of volatile toxicants (Dittrich et al., 2014) .
We compared the RTP with a commercial comparator cigarette (Dittrich et al., 2014) , which was a high-volume BAT cigarette sold in Germany in 2012, the market where the clinical study would be conducted.
The target ISO tar and nicotine yields were, 7.0 and 0.7 mg/cig respectively, in both products. The mainstream smoke yields were matched for the cigarettes to ensure a fair comparison across the studies. Toxicant yields in mainstream smoke (Table 1) were lower with the RTP cigarette than with the comparator product for all tested toxicants other than nicotine, fluorene, phenanthrene, and catechol, irrespective of machine smoking regime. Reductions of up to 25% were Fig. 3 . Construction of the reduced toxicant prototype cigarette (Dittrich et al., 2014) .
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Regulatory Toxicology and Pharmacology 95 (2018) 102-114 seen for polyaromatic hydrocarbons (including benzo[a]pyrene), formaldehyde, and resorcinol, up to 50% for CO, aromatic amines, 1,3-butadiene, more than 50% for most TSNAs, carbonyls, NO, and ammonia, and more than 80% for NNN and volatile species, such as HCN, pyridine, acrylonitrile, 1,3-butadiene, benzene, styrene, naphthalene, methyl ethyl ketone, and cadmium. The reductions were more balanced across the range of measured toxicants than had been seen with earlier prototype designs (McAdam et al., 2012) , which was an important design goal (Dittrich et al., 2014) . In sidestream smoke, measured under ISO smoking parameters (Table 2) , yields of all toxicants apart from some metals (whose yields were below method reporting limits) and catechol (significance not reached), were lower with the RTP than with the commercial comparator cigarette. The reductions ranged from approximately 10% for formaldehyde to over 70% for NNN, with most being around 20-60% (Dittrich et al., 2014) .
We explored whether comparisons of multiple toxicant levels could be simplified by creating a cumulative index (normalisation). Two approaches were examined (McAdam et al., 2012) . The first method was to sum the yields of the 39 toxicants for each cigarette to give a total toxicant yield for each product. This approach, however, was of limited utility because the total yield value is dominated by NFDPM, CO, and nicotine. Even with exclusion of NFDPM, nicotine and CO, yields of toxicants, such as acetaldehyde, isoprene and HCN are still orders of magnitude greater than those of NNN, NNK, and benzo[a]pyrene and, therefore, most constituents were not well represented. The second method gave greater insight into the contribution of all toxicants. A median value was calculated for each toxicant in the commercial Table 1 Mainstream smoke toxicant levels from the RTP and CC cigarettes (n = 5 replicates) (Dittrich et al., 2014 dataset and was normalised to 100, against which the yields of toxicants were scaled. The toxicants were each given an equal weighting for the calculations using the Hoffmann lists as the basis for the toxicological evaluation of each toxicant (Hoffmann and Hoffmann, 1997) . The total of the scaled values gave an overall normalised toxicant value per product. Compared with all the brands in our commercial dataset, the RTP had some of the lowest machine toxicant yields ever published for a combustible cigarette for HCI smoke chemistry (McAdam et al., 2012) . To establish the biological relevance of the reductions, we assessed the RTP using in vitro tests focussed on classical toxicological and disease relevant endpoints and also performed clinical studies. For the clinical study, the appearance of both the RTP and the comparator was changed (from cork to white tipping) paper at the time of switching to enable some level of blind-testing, though it should be noted the physical dimensions of the RTP and the length of filter were quite different when compared to the commercial control product. The clinical study would assess whether exposure and individual risk could be reduced when smokers switched from a conventional cigarette to the RTP cigarette.
In vitro studies measuring toxicological endpoints
We conducted a battery of in vitro tests on particulate matter obtained under the ISO and Health Canada Intense (HCI) machine smoking regimes to assess the toxicity of the RTP in vitro relative to a commercial cigarette (Crooks et al., 2015) . The endpoints that were assessed were bacterial mutagenicity (Ames test), mammalian cell mutagenicity (Mouse Lymphoma Assay), genotoxicity (In Vitro Micronucleus assay) and cytotoxicity (Neutral Red Uptake assay). In the Ames test, the RTP particulate matter was less mutagenic in tester strains TA98 and TA100, irrespective of smoking regime in comparison to the commercial cigarette. The mouse lymphoma assay showed some reductions in gene mutations and chromosome aberrations with the RTP compared with control, but the findings were inconsistent. Changes to chromosome structure and number were also reduced on the in vitro micronucleus test irrespective of the smoking regime. Finally, the neutral red uptake assay identified some differences in cytotoxicity, but none reached significance. These data suggest that reductions in toxicant yields are achievable without new additional genotoxic hazards (Crooks et al., 2015) . Table 2 Sidestream smoke toxicant levels from the RTP and CC cigarettes measured using the ISO machine smoking regime (n = 5 replicates) (Dittrich et al., 2014 21.0 ± 1.4 16.5 ± 0.6 Nicotine (mg/cig) 4.01 ± 0.14 3.13 ± 0.14 CO (mg/cig) 40.0 ± 3.4 25.5 ± 2.9 CO 2 (mg/cig) 305 ± 26 196 ± 11
The BTT used in the RTPs removes at least half of the tobacco protein nitrogen, and more than 40% of the total polyphenols . Reductions in protein nitrogen result in lower levels of aromatic and heterocyclic amine protein products being generated on smoking. These compounds are considered to be the main contribution to cigarette smoke mutagenicity in the Ames assay (Mizusaki et al., 1977) .
Analysis of whole smoke, which included both particulate and vapour phases, rather than just particulate matter confirmed the reduced cytotoxic profile with the RTPs (Fig. 4) (Crooks et al., 2015) . Previous studies (Horinouchi et al., 2016 and Noya et al., 2013) have shown that volatile organic compounds (eg. aldehydes and ketones), are drivers of cigarette smoke responses in cytotoxicity assays. As the RTP contains filter additives that reduced levels of these compounds (≥70%) relative to the commercial cigarette, the reduction in cytotoxicity is due mainly to the carbon and ion-exchange technologies in the prototype filters.
In vitro studies measuring toxicological and disease relevant endpoints
Toxicology testing was also conducted using in vitro models of disease processes. Oxidative stress and inflammation are widely reported to be driving factors in the development of atherosclerosis, chronic obstructive pulmonary disease, and lung cancer. Cigarette smoking increases oxidative stress and inflammation in the lungs and the vascular system (Faux et al., 2009 ). Oke et al., therefore assessed intracellular generation of reactive oxygen species, depletion of reduced glutathione, and secretion of pro-inflammatory cytokines in lung epithelial cells (Oke et al., 2017) , in addition to an endothelial cell migration assay. Cells were exposed to particulate matter and whole smoke to represent the particulate phase and combined particulate and vapour phases. Cigarette smoke aqueous extract was used as a surrogate for whole smoke with the reactive oxygen species and reduced glutathione assays, which are not suitable for whole smoke exposure. All extracts were generated using the ISO smoking regime.
All particulate matter experiments and whole-smoke pro-inflammatory cytokine analysis showed no significant differences between the RTP and conventional cigarettes. In contrast, cigarette smoke aqueous extract from the RTPs induced significantly lower intracellular generation of reactive oxygen species and reduced glutathione depletion than the reference product (Figs. 5 and 6 ). Toxicological testing suggested no increases in toxicological response, and importantly some reductions, particularly for tests responsive to some of the irritants in the vapour phase.
Computational toxicology
Computational toxicological tools were used to assess the potential impact of reducing the toxicant yields to the extent achieved with the RTP. Fowles and Dybing (Fowles and Dybing, 2003) prioritised the hazards for 158 chemical constituents in tobacco smoke based on published cancer potency factors and knowledge of typical yields in smoke. They proposed that 1,3-butadiene, was the most influential volatile compound in relation to cancer, and that four of the top five cancer-related toxicants were aldehydes or small organic compounds, contributing overall around 62.4% of the total cancer risk. They suggested also that metals (e.g., arsenic and cadmium) contributed 18.2% further risk and polyaromatic hydrocarbons only 0.8%. They associated acrolein and acetaldehyde with respiratory disease and HCN and arsenic with cardiovascular disease. Fowles and Dybing noted limitations in their estimates. For instance, the sum of the cancer risk indices they had calculated was five times lower than that attributed to smoking in the USA.
We have investigated various other possible paradigms to calculate risks. For example, we have combined in silico and weight-of-evidence approaches (margin of exposure (MOE), mode of action (MOA)), supplemented with in vitro data. By this method, point of departure values can be included in MOE calculations to support (or not) postulated MOAs for specific toxicants (Cunningham et al., 2012) . Comparison of Fig. 4 . Cell viability of H292 lung epithelial cells exposed to whole smoke from RTP and CC cigarettes for 30 min (n = 9 replicates) (Oke et al., 2017) . Fig. 5 . Intracellular Reactive Oxygen Species (ROS) production in NCI-H292 lung epithelial cells exposed for 1 h to CSEaq from RTP and CC cigarettes, measured by the dichlorofluorescein (DCF) assay (n = 6 replicates) (Oke et al., 2017) . Fig. 6 . Percentage levels of reduced glutathione relative to the untreated control cells in NCI-H292 lung epithelial cells exposed for 1 h to CSEaq of RTP and CC cigarettes, measured by the GSH-Glo assay (n = 6 replicates) (Oke et al., 2017) .
these data with predicted target organ concentrations generated from physiologically based pharmacokinetic modelling is a first step in quantitative extrapolation from in vitro to in vivo. An MOE is the ratio of a benchmark dose to the specific human exposure. The European Food Safety Authority (EFSA, 2012) deems MOEs greater than 10,000 to be low priority for risk management. We have calculated MOE values from a wide range of different studies with various disease endpoints to produce a series of values representative of those in the literature. This enables assessment of the magnitude of the potential risk associated with specific compounds. We defined the following priority bandings: 'top' (MOE 1-10), 'very high priority' (10-100), 'high priority' (100-1000), 'medium priority' (1000-10,000), 'low priority' (10,000-100,000), and 'very low priority' (> 1,000,000). Use of these bandings shows ( Table 3 ) that in all cases, the RTP had an equal or lower priority MOE in comparison to the CC. Furthermore, the MOEs suggest that toxicants in the RTPs, even those that are reduced substantially, would potentially need to be reduced substantially further to have beneficial health effects, perhaps beyond what might be achievable in a cigarette.
Clinical studies
The RTP and comparator commercial cigarette were evaluated further in a 6 month clinical study measuring both BoEs and BoBEs (Shepperd et al., 2013a,b) . The study was reviewed by the Ärzte-kammer Hamburg, Hamburg, Germany (Processing Number PV3824) ethics board in Germany and registered with the US clinical database the International Standard Randomised Controlled Trial Number (ISRCTN) registry (ISRCTN81286286). Healthy volunteer regular smokers smoked the control products for 2 weeks then either continued or switched to an RTP for 6 months (Shepperd et al., 2015) . An ambulatory design was adopted except for several short-term residential clinic visits for biomarker sampling. Data from prospectively assessed ex-smokers and never smokers provided background levels for biomarkers. The study investigated whether BoBE could show differences in smoking statuses and whether concentrations could return to neversmoker levels after switching to the RTP (Haswell et al., 2014) .
We measured 23 urinary BoE (Shepperd et al., 2015) , 5 urinary BoBE, and 22 blood BoBE (Haswell et al., 2014) , as well as urine mutagenicity (Shepperd et al., 2015) . An unexpected but significant and substantial increase in cigarette consumption was seen during the study, both in the arm that continued smoking the commercial control cigarette (an increase of 18.6% cigarettes per day) and the arm that switched to the RTP cigarette (an increase of 12.5% cigarettes per day) (Shepperd et al., 2015) . As this change was anticipated to affect the outcomes of the study, it prompted an alert to the ethics committee, formation of an independent data safety monitoring board, increased monitoring of consumption in electronic diaries and monitoring of cigarette consumption after the study. With these measures in place, both the ethics committee and data safety monitoring board approved continuation of the study. Additionally, we created a bespoke questionnaire to assess the reasons behind increased consumption.
With the exception of 1-OH pyrene, the BoE for the polycyclic aromatic hydrocarbons, increased in the control group and RTP groups ( Table 4 ). The technologies used in the RTP, however, were not expected to substantially reduce these yields. Several BoEs increased in control smokers after switching, presumably due to increases in consumption. Urinary mutagenicity was similar for all smokers at baseline, and differed substantially from that for non-smokers. At the end of the study (EOS), mutagenicity in the RTP group was less than that in the control smoker group, but remained substantially greater than that in never smokers.
The BoE clearly showed the effect of increased consumption, and for the control group, BoE levels typically increased between baseline and the end of the study. However the reductions in the toxicant yield in the RTP were such that reductions in BoE for some toxicants were still seen in those who switched to this product. Good separation of control and Table 4 Percentage changes in biomarker values for RTP cigarette and CC cigarette at the end of a 6-month switching study (Shepperd et al., 2015) . RTP was seen particularly for vapour phase toxicants such as acrolein. The prime reason for increased consumption in control smokers was the supply of free cigarettes, although there was also a perception that the white-tipped version of the control cigarette didn't last as long as the cork-tipped version. For the RTP group, supply of free cigarettes was also the main reason, but reduced satisfaction and a belief that the study cigarettes might be less harmful than the smokers' usual brand were also given as possible reasons when the volunteers were surveyed. The BoBE data provided evidence for processes thought to be key contributors to the development and progression of smoking-related diseases, including oxidative stress and inflammation. Elevated levels of F2-isoprostanes are associated with oxidative stress (Milne et al., 2005; Rahman, 2005) , and levels significantly reduce following smoking cessation (Chehne et al., 2002; Flores et al., 2004; Morrow et al., 1995 and Oguogho et al., 2000) . In our study, isoprostane III levels differed significantly between smokers and non-smokers, but not between smoker controls and RTP smokers. Raised white blood cell counts, an indicator of inflammation, have been associated with smoking-related disease (Fröhlich et al., 2003 and Lao et al., 2009 ), but decrease after smoking cessation (Blann et al., 1997; Hammett et al., 2007 and Lao et al., 2009) . White blood cell counts were significantly and substantially higher in smokers than in non-smokers throughout the study (Haswell et al., 2014) . Values were higher in RTP than in control smokers from baseline to the midpoint of the study and counts increased in the smoker control group by the end of the study, but no changes were significant. Similar patterns were seen for the neutrophil and monocyte sub-fractions.
RTP Smokers
11-dehydrothromboxane B2 (dTx), a metabolite of thromboxane A2, is associated with platelet activation and smoking status (FrostPineda et al., 2011; Lowe et al., 2009; Nowak et al., 1987 and Wennmalm et al., 1991) , which have been shown to decrease in smokers who quit smoking (Rångemark et al., 1993; Roethig et al., 2008 and Saareks et al., 2001) . Throughout the study period, levels of dTx in smoking controls were significantly raised compared with those in nonsmokers. In the RTP group, however, concentrations decreased substantially from baseline and were significantly lower than those in control smoking group at the end of the study (P = 0.002).
An additional benefit of conducting a six month study was that urinary levels of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), a metabolite of NNK, could be analysed over a significant time period. The levels of NNAL were also significantly lower in the RTP group for the duration of the study.
Recruitment of inflammatory cells from the vascular system is an essential part of the damage-repair process in endothelial dysfunction and tissue injury. Elevations in sICAM-1 and MCP-1 have implications for the development of atherosclerosis (Deo et al., 2004; Gross et al., 2012; Kusano et al., 2004 and Piemonti et al., 2009 ). Levels of MCP-1 differed significantly between smokers and non-smokers (Haswell et al., 2014) . A significant reduction was observed in the control group, whereas in the RTP group values did not differ significantly between baseline and EOS. The implications of these findings are unclear, and whether changes have no effect or are detrimental needs to be assessed. By contrast, sICAM-1 levels did not differ between smokers and nonsmokers at baseline, but became significantly higher in both smoking groups (P < 0.001) and significantly higher in the RTP group than in the smoker control group by the end of the study.
Modulation of serum lipids in smokers is related to the development and progression of cardiovascular disease, such as through decreased levels of high density lipoprotein cholesterol (Chelland-Campbell et al., 2008) and raised levels of other lipids and C-reactive protein. Beneficial changes are seen in people who have quit smoking (Chelland-Campbell et al., 2008; Hata and Nakajima, 2000 and Ohsawa et al., 2005) or switched to electronically heated tobacco products (Roethig et al., 2008) . In our study, high density lipoprotein cholesterol levels were significantly lower in smokers than in never-smokers and did not differ between the RTP and smoker control groups.
Comparison of RTP toxicant emissions to those from next generation products
To contextualise emissions from next generation products against our study findings, published aerosol toxicant data was compiled against the list of toxicants proposed for mandated reduction by a WHO study group on Tobacco Product Regulation. (Burns et al., 2008) . The next generation products selected for comparison were a novel tobacco product (Poynton et al., 2017) and an e-cigarette (Margham et al., 2016) , both developed by BAT. To minimise uncertainties that could arise from potential differences in daily consumption of different nicotine products the data is presented on a per-puff basis in Table 5 . These data show that the NGPs lead to substantial reductions in toxicant emissions in comparison to both the CC and RTP cigarettes, and at a magnitude unlikely to be impacted by any differences in daily consumption. These findings are consistent with published data showing per-puff toxicant emissions (as defined by WHO TobReg (Burns et al., 2008) , FDA reporting list (FDA 2012) and Health Canada, 2004 ) from these products to be 95-99% lower than from a reference cigarette (Margham et al., 2016; Poynton et al., 2017) . These findings suggest that the NGPs should be considered as candidates for reduced risk product assessment.
Regulatory proposals on toxicants
TobReg proposed mandated ceilings for emissions of nine toxicants, Tables 5 and 6 (Burns et al., 2008; World Health Organisation, 2015) . Their proposals are precautionary, based on the substances being known to be harmful rather than there being a proven specific link between reduced levels and lowered risk of human disease (World Health Organization, 2008) . The TobReg approach is complex, with three different models advanced. Two models focus upon the establishment of ceiling values calculated as the ratios of toxicant emissions to nicotine when measured under the HCI smoking regime. With the first model, all tobacco products in a market must be assessed and emission ratios ranked from low to high, with the middle product becoming the reference for all others. For the two TSNAs, the ceiling value would be the value of the median product, and for the other seven toxicants it would be 125% of the value for the median product. To be approved for sale, products (new and existing) would need to comply with all nine ceilings. These proposals, therefore, are likely to result in high non-compliance rates. For example, with NNN and NNK, 50% of (Dittrich et al., 2014) . b RTP cigarette (Dittrich et al., 2014) . c Hybrid Tobacco Product (Poynton et al., 2017) . d Electronic Cigarette (Margham et al., 2016) .
products would automatically fail each TSNA limit. In the second model TobReg defined two sets of fixed toxicant/nicotine ratio ceilings-one for flue-cured product markets and one for US-blended product markets-for those countries with limited laboratory capacity (Burns et al., 2008) . These would be applied by regulators without the need to identify the relevant values in their own market. A more recent WHO TobReg report on smoke toxicants (World Health Organisation, 2015 ) developed a third model wherein toxicant ceilings would be set at a value three times the lowest toxicant emission of the products on the market.
We collected data for four countries (sampling 80-97% of the products within those markets) with distinct product attributes: predominately flue-cured cigarettes, predominately American-blended cigarettes, multiple charcoal filtered and reduced circumference cigarettes, and mixed blend styles. Laboratory testing took a considerable time and was costly. Within-product variation over time was sufficiently large to be a major determinant of whether a product passed or failed to meet TobReg ceiling proposals (Eldridge et al., , 2017 . Other key drivers for products failing to meet the proposed limits were the TNSAs, NNN and NNK. Individually, failures to meet ceilings were less extensive for the other seven toxicants, but the cumulative effect of needing to be below all nine ceilings led to most products (typically 72-79%, around 600 products out of 781 tested) failing (Eldridge et al., 2017) . The impact of fixed ceiling values (model 2) was to produce generally higher levels of non-compliance of between 70 and 100% of the products from these exemplar markets; similar conclusions were found for third model (Eldridge et al., 2017 ).
The RTP we tested passed all individual toxicant ceilings under all three models (Tables 6 and 7) , with the RTP having emissions in the range of 20-80% of the proposed ceilings. These findings raise concerns as to the robustness of the WHO TobReg proposals; the failure of an entirely compliant product to effect noticeable clinical benefits to its consumers provides little evidence that these proposals would positively impact incidence of smoking related diseases. However, it is also possible that longer time-scales may be needed for benefits to emerge.
The NGPs also passed the TobReg limits, but by a considerably greater margin than the RTP, reflecting the lower toxicant emissions from the NGPs. These emissions were 1-3 orders of magnitude lower than the TobReg ceilings. These NGPs may therefore reasonably be regarded as candidate reduced risk products, and therefore further investigation, including pre-clinical and clinical studies, is warranted.
Discussion
Evaluation of a reduced toxicant prototype cigarette in pre-clinical and clinical studies demonstrated substantial reductions in broad classes of laboratory measured toxicant emissions, lowered activities of in vitro assays, as well as reduced in vivo exposure to toxicants. However, the risk profile associated with its use (as monitored through BoBE) did not differ from that of a conventional cigarette. Overall, of the suite of BoBEs examined, the RTP demonstrated potentially beneficial effects only for levels of 11-dehydrothromboxane B2 but had potentially adverse effects on sICAM-1 levels. Thus, while our data do not challenge the basic premise that smoking-related diseases are caused by prolonged and repeated exposure to toxicants or that risks are dose related, they show little evidence that the modifications introduced in the RTP modify risk.
The reasons for these observations are unclear. Literature reports indicate that changes in BoBE levels following smoking cessation occur within the time frame of the RTP study (Shepperd et al., 2015) . However, six months might not have been long enough to detect meaningful BoBE changes in subjects who continue to smoke, albeit with a reduced toxicant yield product. A substantially longer study may be required to allow wider changes in BoBE to be observed. Also, it is possible that few or none of the toxicants reduced in the RTP have causative roles in smoking-related diseases. Computational toxicological assessment to Table 6 Comparison of RTP and NGP emissions to WHO TobReg proposed ceiling values (model 1 and model 2) (Eldridge et al., 2017; Burns et al., 2008) . Analyte Table 5 footnotes.
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Regulatory Toxicology and Pharmacology 95 (2018) 102-114 prioritise toxicants as drivers of disease also suggests that levels of some respiratory irritant precursors (e.g., acrolein and the aldehydes) might need to be reduced more than achieved with the RTP to have any effects on BoBE. Ambulatory clinical trials of the kind performed with the RTP are largely blind to subject-product compliance, and the degree to which the subjects use the test product exclusively outside of the clinical setting. Significantly increasing cigarette consumption, or frequently smoking other cigarette brands, between clinical visits could diminish the potential of the RTP to reduce overall toxicant exposure and any consequential potential health benefits. Most BoE have shorter half-life times than BoBEs, and significant non-compliance of this kind could minimise changes in BoBE while registering significant BoE reductions.
Compliance checking is challenging when one cigarette product is switched to another in a trial, as the presence or absence of any combustion markers cannot be used to monitor compliance, unlike with cessation studies or when a cigarette is switched to a non-combustible product. In the RTP trial a number of steps were taken to monitor compliance. These included: i) use of electronic diaries to monitor cigarette consumption, ii) comparison of numbers of collected study cigarettes with diary entries, iii) interrogation of changes in long-lived Biomarkers of Effective Dose (BoED -such as DNA and protein adducts of 4-aminobiphenyl and acrylonitrile) in comparison to their urinary BoE, iv) comparison of changes in certain slow changing Biomarkers of Exposure (such as NNAL the metabolite of NNK), and their ratios to nicotine (to account for consumption changes) in comparison to laboratory smoke yield reductions.
Significant increases in cigarette consumption were observed in the ambulatory periods of the RTP study in comparison to those measured in the clinical stages. Reductions in BoED were slightly smaller than with their corresponding BoE; similar findings were observed with changes in NNAL/TNeq in comparison to smoke yield reductions, but in both cases alignment between the two comparators was good. From these observations, we can conclude that some degree of non-compliance may have existed during ambulatory study arms, but without a substantial impact on study findings.
Given the overall lack of response in BoBE with RTP users, these results point to a minimum toxicant exposure level above which improvements in risk profile are unlikely to be found. This is a vital finding as future candidate reduced risk products would need to demonstrate the likelihood of toxicant exposures lower than those measured for the RTP. Comparison of toxicant emissions from Next Generation Products to those from the RTP and control cigarette suggest that NGPs meet this criterion, and therefore have the potential to reduce the risks associated with smoking. However, although toxicant reductions from NGPs were 95-99% lower than from a reference cigarette, the reductions were not complete, and therefore some level of risk associated with their use may exist.
Conclusions
This paper illustrates that it is possible to develop prototype cigarette products that can reduce toxicant emissions and exposure compared with conventional cigarettes. However, the reductions in emissions (despite meeting toxicant emission ceilings identified by a WHO study group) and subsequent exposure did not manifest beneficial disease relevant health outcomes in a long term clinical study, with little change in BoBE after 6 months' use.
Thus, while we cannot say with certainty that there would be no public health benefit associated with the observed toxicant reductions, as proposed by WHO TobReg, it is likely that more substantial reductions in exposure will be needed to produce measurable reductions in health risks. We conclude, therefore, that there is insufficient evidence to support cigarettes with reduced toxicant emissions as a distinct category in a risk continuum.
These results also point to a minimum toxicant exposure baseline, that candidate RRPs would need to overcome before consideration for testing via full pre-clinical and clinical assessment. A comparison of the emissions from Next Generation Products show that they have much lower toxicant levels than both conventional and RTP cigarettes. Next generation products therefore represent a highly promising approach for reducing the harm associated with cigarette smoking. For superscript letters a, b, c, d refer to Table 5 footnotes.
